The Supreme Court Reverses the Federal Circuit’s Decision in Caraco v. Novo Nordisk


The U.S. Supreme Court issued its decision in Caraco v. Novo Nordisk, holding that Hatch-Waxman permits generic drug companies to counterclaim to force correction of a use code that inaccurately describes the brand company’s patent as covering a particular method of using the drug in question. While the case centered on an issue of statutory wording, the Court’s decision depended upon the broader context of the Hatch-Waxman Act. In supporting its decision, the Court emphasized that “[t]he statutory scheme, in other words, contemplates that one patented use will not foreclose marketing a generic drug for other unpatented ones.”


The complex regulatory framework of the Hatch-Waxman Act is designed to strike a delicate balance between innovation and competition in the pharmaceutical industry. The Supreme Court’s decision in Caraco v. Novo Nordisk will have an important impact on that balance by giving generic manufacturers a means by which to challenge the scope of a brand company’s broadly drafted patent use code narrative designed to impede approval of generic drug applications.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Civil Procedure Updates, Civil Remedies Updates, Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »